MSM Stock Overview
Engages in the distribution of implants and other medical materials used in the treatment of musculoskeletal system diseases and regenerative medicines in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Massmedica S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł4.86 |
| 52 Week High | zł9.00 |
| 52 Week Low | zł2.26 |
| Beta | 0.12 |
| 1 Month Change | -18.32% |
| 3 Month Change | -24.06% |
| 1 Year Change | 84.09% |
| 3 Year Change | -11.64% |
| 5 Year Change | 64.19% |
| Change since IPO | -37.69% |
Recent News & Updates
We Ran A Stock Scan For Earnings Growth And Massmedica (WSE:MSM) Passed With Ease
Feb 21
Massmedica S.A. (WSE:MSM) May Have Run Too Fast Too Soon With Recent 32% Price Plummet
Dec 05Recent updates
We Ran A Stock Scan For Earnings Growth And Massmedica (WSE:MSM) Passed With Ease
Feb 21Massmedica S.A. (WSE:MSM) May Have Run Too Fast Too Soon With Recent 32% Price Plummet
Dec 05Massmedica S.A.'s (WSE:MSM) 26% Share Price Surge Not Quite Adding Up
Oct 12Massmedica S.A.'s (WSE:MSM) Shares Climb 31% But Its Business Is Yet to Catch Up
Aug 07There's Reason For Concern Over Massmedica S.A.'s (WSE:MSM) Massive 44% Price Jump
Jun 20Optimistic Investors Push Massmedica S.A. (WSE:MSM) Shares Up 41% But Growth Is Lacking
Mar 07Calculating The Intrinsic Value Of Massmedica S.A. (WSE:MSM)
Jan 05I Ran A Stock Scan For Earnings Growth And Massmedica (WSE:MSM) Passed With Ease
Sep 14Massmedica S.A.'s (WSE:MSM) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Dec 15
Shareholder Returns
| MSM | PL Healthcare | PL Market | |
|---|---|---|---|
| 7D | -7.4% | -1.5% | 0.5% |
| 1Y | 84.1% | 5.7% | 5.4% |
Return vs Industry: MSM exceeded the Polish Healthcare industry which returned 5.7% over the past year.
Return vs Market: MSM exceeded the Polish Market which returned 5.4% over the past year.
Price Volatility
| MSM volatility | |
|---|---|
| MSM Average Weekly Movement | 11.7% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in PL Market | 10.3% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: MSM's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: MSM's weekly volatility has decreased from 17% to 12% over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 18 | Marek Mlodzianowski | www.massmedica.com |
Massmedica S.A. engages in the distribution of implants and other medical materials used in the treatment of musculoskeletal system diseases and regenerative medicines in Poland. It offers products in the field of reconstructive, regenerative, anti-aging, and aesthetic medicine. The company’s products include dietary supplements, skin care cosmetics, sun protection creams, tools for home treatments, and intra-articular injections for regeneration of the knee joints.
Massmedica S.A. Fundamentals Summary
| MSM fundamental statistics | |
|---|---|
| Market cap | zł11.54m |
| Earnings (TTM) | zł625.88k |
| Revenue (TTM) | zł32.61m |
18.8x
P/E Ratio0.4x
P/S RatioIs MSM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MSM income statement (TTM) | |
|---|---|
| Revenue | zł32.61m |
| Cost of Revenue | zł20.13m |
| Gross Profit | zł12.48m |
| Other Expenses | zł11.86m |
| Earnings | zł625.88k |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 38.28% |
| Net Profit Margin | 1.92% |
| Debt/Equity Ratio | 101.9% |
How did MSM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 21:08 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Massmedica S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.